The dog stands still, a sensor array resting gently against its skull. On a nearby screen, a waveform dances in real time, a direct readout of the animal's olfactory bulb as it processes the world. This is not a veterinary procedure, but a data collection event. General Sense, a Florida deeptech company, is not training detection dogs; it is turning them into high-fidelity, biological sensors for a chemical intelligence layer that does not yet exist [SOSV].
The Nose-Computer Interface
General Sense's core technology is a Nose-Computer Interface (NCI), a hardware and software stack that reads neural signals directly from a dog's olfactory bulb and translates them into digital data streams [SOSV]. The company, which operated previously as Canaery, frames this not as a tool for a single handler but as foundational infrastructure. Every deployed animal, the thinking goes, feeds a shared model that grows smarter with each sniff, creating a networked sensing platform with no direct market equivalent [SOSV]. The ambition is to own what it calls a frontier data modality: the chemical lobe for embodied intelligence. This is a bet on data acquisition at the biological source, long before any synthetic sensor can match the combinatorial sensitivity of a mammalian nose.
A Wedge in Security and Defense
The initial market is pragmatic. General Sense is starting with security and defense applications, where detection dogs for explosives, narcotics, and contraband are already deployed but limited by scale and subjective handler interpretation [LinkedIn]. The NCI, developed in collaboration with Lawrence Livermore National Laboratory, aims to upgrade these existing assets, allowing a single dog to identify multiple target odors simultaneously and stream that data for centralized analysis [eenewseurope.com]. The long-term mission, however, stretches far beyond the checkpoint. The company's stated goal is to build a sensory reasoning model that gives artificial intelligence a generalizable understanding of the chemical world, with applications in medical diagnostics and environmental monitoring [LinkedIn].
The Team and the Traction
The founders bring a blend of neuroscience and defense-adjacent engineering to the problem. CEO Westley Dang holds a PhD in neuroscience from The Scripps Research Institute and spent six years investing in deep tech at SOSV's IndieBio program before taking the helm [RocketReach, LinkedIn]. Co-founder and COO Gabriel Lavella is a former DARPA engineering advisor, providing a crucial bridge to the defense and national security ecosystems that are the logical first customers [My TechDecisions, Businesswire]. Their early backing suggests investors are buying the foundational data argument. The company has raised at least $4 million in a seed round led by Breakout Ventures, with SOSV as a portfolio investor, and a further $5 million round was reported in mid-2024 [SOSV, 2022], [Wellfound, July 2024].
| Role | Name | Key Background |
|---|---|---|
| CEO | Westley Dang | PhD in Neuroscience (Scripps), former deep tech investor at SOSV/IndieBio |
| Founder & COO | Gabriel Lavella | Former DARPA engineering advisor |
Where the Scent Trail Could Fade
For all its poetic ambition, General Sense's path is paved with profound technical and commercial uncertainties. The company operates in a field with no proven commercial precedents, making its timeline and capital needs difficult to forecast.
- The biological black box. Decoding neural signals into specific, actionable chemical identifiers is an extraordinarily complex neuroscientific challenge. The company must prove its interface can reliably distinguish between thousands of odorants in uncontrolled, real-world environments, not just in a lab.
- The scaling paradox. The model depends on a network of biologically limited nodes,trained dogs. Acquiring, caring for, and deploying enough animals to generate the data density needed for a robust AI model is a logistical and ethical undertaking of significant scale.
- The silent market. There is no public record of paid customer deployments or pilot partnerships. While targeting government agencies is strategic, sales cycles are long, budgets are political, and incumbents are entrenched. The absence of named traction leaves the commercial wedge unproven.
The company's quiet progress, including what it calls the world's first real-time detection of the chemical world from neural activity in 2025, suggests it is hitting technical milestones [Internexxus, 2026]. But the leap from a research prototype to a reliable, field-deployed system that can be sold on a contract is the true test. The next twelve months will be critical for moving from a compelling demo to a documented, repeatable sale.
Ultimately, General Sense is answering a question that most of tech has ignored: what does the world smell like to a machine? We have given AI eyes and ears through cameras and microphones, but the chemical spectrum,the domain of disease, contamination, and hidden threats,has remained a silent channel. The company is betting that the key to opening it isn't a better lab-on-a-chip, but a more elegant partnership with biology itself. The cultural question it poses is whether the most advanced chemical sensor for the digital age was evolved, not invented.